This page shows the latest EngMab news and features for those working in and with pharma, biotech and healthcare.
It already has a BCMA candidate in-house after buying EngMab for $625m last year, for example.
It's still adding to its cancer stable too, with recent examples including its $600m deal for Swiss biotech EngMab - signed last October - the acquisition of marizomib from Triphase Accelerator for
Consolidates position as top company in current multiple myeloma market. Swiss start-up EngMab has been snapped up by Celgene in a $600m deal that adds another multiple myeloma candidate to ... Privately-held EngMab's lead programme focuses on bispecific
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Another company rarely away from the deal headlines is Celgene. This month Celgene acquired the company EngMab paying $600m for the privilege. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....